Therefore, these cells serve as an ideal CML model expressing CD25, making them the optimal choice for assessing the effectiveness of CD25 CAR-NK92 cells. The gene discussed is IL2RA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.